Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23607126 | 0.84 | NPC1 (0.39) | — | |
| SCHEMBL25132256 | 0.79 | PIM1 (0.49) | PIM1PARP1PIM3EGLN2FTO | |
| SCHEMBL23607123 | 0.78 | PRKCA (0.48) | PIM1TLR7PIM3EGLN2FTO | |
| SCHEMBL23607128 | 0.72 | PIM1 (0.46) | PIM1PIM3EGLN2FTO | |
| SCHEMBL18740245 | 0.68 | EPHX2 (0.59) | EPHX2 | |
| SCHEMBL23607121 | 0.68 | ATR (0.51) | PIM1PRKCI | |
| SCHEMBL25131885 | 0.67 | KDM4E (0.52) | PIM1PIM3GRM4PRKCI | |
| SCHEMBL23607118 | 0.67 | PIM1 (0.49) | PIM1PIM3PRKCI | |
| SCHEMBL10571731 | 0.64 | PRKD1 (0.49) | EPHX2 | |
| SCHEMBL22597906 | 0.62 | EPHX2 (0.49) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2021133917-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | SMARCC1, SMARCE1, SMARCA1 | PIM1 1216/4885PARP1 56/4885TLR7 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.